This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA521782; GEO: GSE126281 |
| Type | Umbrella project |
| Submission | Registration date: 8-Feb-2019
Rhelixa, Inc. |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| SRA Experiments | 32 |
| Other datasets |
| BioSample | 32 |
| GEO DataSets | 5 |
Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells encompasses the following 4 sub-projects:
| Project Type | Number of Projects |
| Other | 1 |
|
| Transcriptome or Gene expression | 3 |
BioProject
accession | Organism | Title |
|---|
| PRJNA521844 | Mus musculus | IFN-α-producing proliferating myeloid cells reveal type I IFN-stimulating gene signature (Rhelixa, Inc.) | | PRJNA521845 | Mus musculus | Local administration of IFN-α-iPSC-pMCs alters gene expression profiles in tumor microenvironment. (Rhelixa, Inc.) | | PRJNA521846 | Mus musculus | Characterization of tumor-infiltrating T cells by TCR-β repertoire analyses (Rhelixa, Inc.) |
|